1. 6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial. (September 2015) Authors: Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M.; Bushnell, D.; Caplin, M.; Baum, R.P.; Mittra, E.; Hobday, T.; Hendifar, A.; Oberg, K.; Lopera Sierra, M.; Ruszniewski, P.; Kwekkeboom, D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S710 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SP-0570: Neuroendocrine tumours - personalised diagnosis and treatment using radiolabelled peptides. (April 2016) Authors: Baum, R.P.; Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M.; Bushnell, D.; Caplin, M.; Hobday, T.; Hendifar, A.; Oberg, K.; Lopera Sierra, M.; Kwekkeboom, D.; Ruszniewsk, P.; Krenning, E.; Mittra, E. Journal: Radiotherapy and oncology Issue: Volume 119(2016)Supplement 1 Page Start: S274 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗